Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer
Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.
Related Articles
FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma
The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm
Therapy for chronic myelomonocytic leukemia (CMML) has made little progress during the last 15 years, mainly because standard therapies have been adopted f
Finding passion and community
The Fred Hutch Postbaccalaureate Scholar Program provides recent college graduates $50,000 a year and benefits as full-time Fred Hutch employees with an expanded emphasis on…
Fox Chase Cancer Center’s Disha Sawhney Recognized With Future Five Award From Medical Group Management Association
PHILADELPHIA (November 11, 2024) — Disha Sawhney, FACHDM, FRSPH, Manager of Service Line Operations at Fox Chase Cancer Center, was recently awarded a 2024 Future…
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Clinical Oncology Bridges Gaps Between Medical Oncology, Radiation Oncology, and Clinical Research: With D. Ross Camidge, MD, PhD; and Duncan McLaren, MBBS, BSc, FRCR, FRCP
Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.
Lactylation in cancer: Current understanding and challenges
Lactylation, a recently identified post-translational modification, has initially been linked to gene transcription regulation through epigenetic mechanisms. However, its role in tumorigenesis—whether as a major…
Toripalimab Plus Chemo: A First-Line Option for ES-SCLC?
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed…
FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
Low-Risk Individuals Should Not Currently Be Screened for… : Oncology Times
An abstract is unavailable.
